[Influence of fibrinolysis inhibitors on anticoagulant induced hemorrhages].
D062365:Aminobenzoates / Q000627:therapeutic use; D000614:Aminocaproates / Q000627:therapeutic use; D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D001593:Benzyl Compounds / Q000627:therapeutic use; D003374:Coumarins / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced* / Q000188:drug therapy; D007192:Indenes / Q000627:therapeutic use; D007659:Ketones / Q000627:therapeutic use; D008297:Male; D051379:Mice; D011817:Rabbits; D051381:Rats; D013300:Streptokinase / Q000627:therapeutic use
D062365:Aminobenzoates; D000614:Aminocaproates; D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D001593:Benzyl Compounds; D003374:Coumarins; D003509:Cyclohexanecarboxylic Acids; D007192:Indenes; D007659:Ketones; D013300:Streptokinase
Untersuchungen über die Beeinflussung von Antikoagulantienblutungen durch Fibrinolysehemmstoffe.